BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.
During the Period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.
During the Period, the following stock warrants have expired.
| Number of warrants | Issue date | Original expiry date | Amended expiry date |
| 1,414,286 | February 27, 2024 | August 27, 2025 | August 5, 2026 |
| 650,000 | March 22, 2024 | September 22, 2025 | August 5, 2026 |
| 1,125,000 | May 9, 2024 | November 9, 2025 | August 5, 2026 |
| 3,502,931 | June 5, 2024 | December 5, 2025 | August 5, 2026 |
| 8,333,333 | September 20, 2024 | March 20, 2026 | September 5, 2026 |
| 2,655,691 | October 25, 2024 | April 25, 2026 | September 25, 2026 |
As at the date of this press release, the following stock warrants are outstanding and can be exercised at the price of $0.40 per common share.
| Number of warrants | Issue date | Original expiry date | Amended expiry date |
| 6,715,369 | February 5, 2025 | August 5, 2026 | June 5, 2027 |
| 13,494,459 | December 5, 2025 | June 5, 2027 | n/a |
| 513,248 | December 5, 2025 | June 5, 2027 | n/a |
DIAGNOS would like to thank the shareholders for their continuous support.
The currency stated in this press release is the Canadian dollar.
About DIAGNOS
DIAGNOS is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. DIAGNOS manufactures CARA System, a software platform which assists health specialists in the detection of retinal eye pathologies. CARA System is currently licensed for commercialization in Canada and Saudi Arabia. By developing innovative products based on AI technologies, DIAGNOS’ solutions provide healthcare clinicians with valuable information that refines diagnostic accuracy, streamlines workflows, and improves patient outcomes.
Additional information is available at www.diagnos.com and www.sedarplus.com.
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca
